Xiaoling Li

机构：Yanshan University, Heilongjiang Academy of Land Reclamation Sciences, Children's Hospital of Chongqing Medical University, Liaoning Cancer Hospital & Institute, Chongqing Medical University · ORCID：0009-0003-7903-9708

发表论文 55 篇 · 总被引 95 次 · h-index 5

代表论文

• Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial (2025 · Nature Medicine · 被引 34)
• Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer (2025 · Nature Communications · 被引 5)
• Efficacy and safety of cadonilimab in recurrent/metastatic solid tumors including ICI-treated tumors in clinical practice: Cohorts of head and neck squamous cell carcinoma and cervical cancer. (2025 · Journal of Clinical Oncology · 被引 1)
• Figure S5 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance (2025)
• Table S1-S9 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance (2025)
• Figure S7 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance (2025)